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Abstract
Background: Fuzheng Huayu recipe (FZHY), a compound of Chinese herbal medicine, was reported to improve
liver function and fibrosis in patients with hepatitis B virus infection. However, its effect on nutritional fibrosing
steatohepatitis is unclear. We aimed to elucidate the role and molecular mechanism of FZHY on this disorder in
mice.
Methods: C57BL/6 J mice were fed with methionine-choline deficient (MCD) diet for 8 weeks to induce fibrosing
steatohepatitis. FZHY and/or heme oxygenase-1 (HO-1) chemical inducer (hemin) were administered to mice,
respectively. The effect of FZHY was assessed by comparing the severity of hepatic injury, levels of hepatic lipid
peroxides, activation of hepatic stellate cells (HSCs) and the expression of oxidative stress, inflammatory and
fibrogenic related genes.
Results: Mice fed with MCD diet for 8 weeks showed severe hepatic injury including hepatic steatosis, necro-
inflammation and fibrosis. Administration of FZHY or hemin significantly lowered serum levels of alanine
aminotransferase, aspartate aminotransferase, reduced hepatic oxidative stress and ameliorated hepatic
inflammation and fibrosis. An additive effect was observed in mice fed MCD supplemented with FZHY or/and
hemin. These effects were associated with down-regulation of pro-oxidative stress gene cytochrome P450 2E1, up-
regulation of anti-oxidative gene HO-1; suppression of pro-inflammation genes tumor necrosis factor alpha and
interleukin-6; and inhibition of pro-fibrotic genes including a-smooth muscle actin, transforming growth factor beta
1, collagen type I (Col-1) and Col-3.
Conclusions: Our study demonstrated the protective role of FZHY in ameliorating nutritional fibrosing
steatohepatitis. The effect was mediated through regulating key genes related to oxidative stress, inflammation and
fibrogenesis.
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Background
Non-alcoholic steatohepatitis (NASH) represents the
most common chronic liver disease associated to envir-
onment and lifestyle conditions in a context of genetic
predisposition. It has become one of the leading causes
of severe hepatic dysfunction in the modern world [1].
Liver fibrosis, through which NASH develops into cir-
rhosis, is a healing response to chronic injuries. Fibro-
g e n e s i si n v o l v e sm u l t i f a c t o r i a l oxidative stress, cytokine
imbalance, and hepatic stellate cells (HSCs) activation.
Unfortunately, today there is no specific and effective
antifibrotic therapy available, therefore it is rather
important to recognize liver fibrosis in its early stages
and search for new treatment method to prevent further
progression.
Fuzheng Huayu recipe (FZHY), a compound of Chinese
herbal medicine, consists of six Chinese medicinal herbs,
namely Semen Persicae, Radix Salvia Miltiorrhizae,
Gynostemma Pentaphyllammak, Cordyceps, Pollen Pini,
Fructus Schisandrae Chinensis [2]. The previous clinical
trials showed that FZHY could significantly improve clin-
ical symptoms, liver function, reverse hepatic fibrosis and
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any medium, provided the original work is properly cited.decrease portal pressure in patients with chronic hepatitis
B and liver cirrhosis [3,4]. However, the effect of FZHY
on fibrosing steatohepatitis remains unknown. In this
study, we investigated the role and molecular basis of
FZHY in the evolution of nutritional fibrosing steatohe-
patitis in mice.
Material and methods
Animals and treatments
Eight-week-old male C57BL/6 J mice with body weight
between 20-25 g were obtained from the Experimental
Animal Center of Chinese Academy of Medical Sciences,
and were bred in a temperature-controlled animal facility
with a 12-h light-dark cycle. They had free access to water
and were allowed to adapt to their food and environment
for 1 week before the start of the experiment. The C57BL/
6 J mice were randomly divided into 5 groups (6 mice per
group): 1) MCD group, mice fed methionine-choline defi-
cient diet (ICN, Aurora, Ohio); 2) control group, mice fed
MCD diet supplemented with choline bitartate (2 g/kg)
and DL-methionine (3 g/kg) (ICN, Aurora); 3) MCD +
hemin group, mice fed MCD diet administered with heme
oxygenase-1 (HO-1) chemical inducer hemin (30 μmol/
kg) by intraperitoneal (i.p.) injections three times per
week; 4) MCD + FZHY group, mice fed MCD diet supple-
mented with FZHY (15 g/kg
.d, Huanghai pharmaceutical
company limited, Shanghai, China); 5) MCD + FZHY +
hemin group, mice fed MCD diet administered with
FZHY and hemin. The duration of the experiment is up to
8 weeks. During the experiments, their body-weight and
rate of diet consumption were recorded. All of the animals
were sacrificed after overnight fasting at the end of experi-
ments. Blood samples were collected from femoral artery
for biochemical analysis. Livers were weighed and fixed in
10% formalin for histological analysis or snap-frozen in
lipid nitrogen followed by storage at -80°C freezer until
required. All the protocols and procedures were per-
formed following the guidelines of the Hebei Committee
for Care and Use of Laboratory Animals and were
approved by the Animal Experimentation Ethics Commit-
tee of the Hebei Medical University.
Biochemical analysis
Serum alanine aminotransferase (ALT) and aspartate ami-
notransferase (AST) levels were measured by the enzy-
matic kinetic method using an automatic biochemical
analyzer (Olympus UA2700, Japan) according to the man-
ufacturer’s instructions. The extent of lipid peroxidation in
the liver homogenate was estimated by measuring the con-
centration of malondialdehyde (MDA) using an OxiSelect
thiobarbituric acid-reactive substances (TBARS) Assay Kit
according to the manufacturer’s instructions (Cell Biolabs,
San Diego, CA).
Histological analysis
Hematoxylin and eosin stained and Masson trichroma-
tism stained paraffin-embedded liver sections (5 μm
thick) were scored for hepatic steatosis, inflammation
and fibrosis as described previously [5,6] in accordance
with the Brunt’s criteria [7] and the histological scoring
system for NAFLD issued by the Pathology Committee
of the Nonalcoholic Steatohepatitis Clinical Research
Network [8].
Quantitative real-time reverse transcription polymerase
chain reaction (RT-PCR) analysis of hepatic messenger
RNA expression
Total RNA was isolated from frozen liver tissues using
Trizol Reagent (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions. The hepatic messenger RNA
(mRNA) levels of cytochrome P450 2E1 (CYP2E1), HO-1,
tumor necrosis factor alpha (TNF-a), interleukin-6 (IL-6),
a-smooth muscle actin (a-SMA), transforming growth
factor beta 1 (TGF-b1), collagen type I (Col-1) and Col-3
were determined by quantitative Real-Time reverse tran-
scription polymerase chain reaction (qRT-PCR) using the
ABI PRISM 7300 sequence detection system (Applied Bio-
systems, Foster, CA) with SYBR Green Reagent (Invitro-
gen, Carlsbad, CA). Expression levels of the target genes
were normalized against an endogenous reference gene
glyceraldehydes 3-phosphate dehydrogenase (GAPDH).
The specific primers for CYP2E1, HO-1, TNF-a, IL-6, a-
SMA, TGF-b1, Col-1 and Col-3 were designed using Pri-
mer Express 2.0 (Table 1). All data were obtained using
Sequence Detector Software (Applied Biosystems, Foster,
CA).
Western blotting analysis of hepatic protein expression
Total protein was extracted and concentration was mea-
sured by the Bradford method (DC protein assay; Bio-
Rad, Hercules, CA) as previously described [9]. Equal
amounts of protein (100 μg/well) were loaded onto 10%
SDS-PAGE for each sample and proteins were trans-
ferred onto equilibrated polyvinylidene difluoride mem-
branes (Amersham Biosciences, Buckinghamshire, UK)
by electroblotting. The membranes were incubated with
primary antibodies of CYP2E1, HO-1, a-SMA, TGF-b1,
Col-1 and Col-3 (Santa Cruz Biotechnology, Santa Cruz,
CA) respectively overnight at 4°C. Membranes were
further incubated with secondary antibody for 1 h at
room temperature. Proteins were detected by enhanced
chemiluminescence (ECL; Amersham Corporation,
Arlington Heights, CA) and bands were quantified via
scanning densitometry using the digital Kodak Gel Logic
200 (Carestream Molecular Imaging, Newhaven, CT).
Individual levels of hepatic protein were normalized with
b-actin.
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All data are presented as mean ± SD (standard devia-
tion). Statistical analysis was performed by one-way ana-
lysis of variance (ANOVA) and Student-Newman-Keuls
test for evaluating differences between groups using
SPSS 13.0 (v. 13.0; SPSS Inc., Chicago, IL). A P-value of
less than 0.05 was considered statistically significance.
Results
FZHY lowered the serum levels of ALT and AST in mice
fed with MCD diet
As shown in Figure 1, mice fed an MCD diet showed sig-
nificantly higher serum ALT and AST levels (P < 0.001)
compared with control group, indicating hepatic injury. A
significant reduction of serum ALT and AST (P <0 . 0 0 1 )
were noticed after FZHY with or without hemin adminis-
tration. An additive effect was observed in the mice treated
with FZHY and hemin. In addition, FZHY lowered hepatic
oxidative stress as demonstrated by TBARS assay, the
combination of FZHY and hemin showed a better effect
on suppressing MDA concentrations (Figure 1C).
Effect of FZHY on hepatic inflammation and fibrosis in
mice fed with MCD diet
The liver sections from mice fed an MCD diet alone
exhibited disordered lobule structure, severe macrostea-
tosis, spot or focal hepatocyte necrosis and inflammatory
infiltration (Figure 2A), portal fibrosis and fibrous sep-
tum (Figure 2B). However, mice treated with FZHY in
the presence or absence of hemin could notably amelio-
rate hepatic steatosis, necrotic inflammation (Figure 2A)
and improved liver fibrosis (Figure 2B). Co-administra-
tion of FZHY and hemin had a further improved effect
on hepatic inflammation and fibrosis (Figure 2B).
Effect of FZHY on the expression of oxidative related
genes CYP2E1 and HO-1
The mRNA and protein expressions of lipid peroxidation
mediator CYP2E1 and anti-oxidative stress factor HO-1
were induced by MCD diet (Figure 3A and 3B). Adminis-
tration of FZHY could reduce hepatic expression of
CYP2E1 and HO-1, which was concomitant with amelio-
rated hepatic steatosis, inflammation and fibrosis induced
by MCD-treatment. A further inhibition of CYP2E1
expression was observed in FZHY plus hemin group.
FZHY regulated expression of inflammation related genes
To seek an explanation for the decreased serum transami-
nases and ameliorated liver histology by FZHY, we investi-
gated hepatic mRNA expression levels of inflammatory
genes TNF-a and IL-6. Relative to control mice, hepatic
TNF-a and IL-6 were up-regulated in MCD diet-fed mice
(P < 0.001) (Figure 4), which was significantly blunted by
treatment with FZHY or hemin. The combination of
FZHY and hemin led to a further effect on preventing the
TNF-a (P < 0.01) and IL-6 (P < 0.01) mRNA expression
compared with MCD + hemin group.
FZHY suppressed hepatic expression of pro-fibrosis genes
in MCD diet-induced fibrosing steatohepatitis
To evaluate the mechanism of the effect of FZHY on
fibrosing steatohepatitis, we assessed the hepatic expres-
sion levels of fibrosis related genes. In MCD feeding
mice, mRNA and protein expression of alpha-smooth
muscle actin (a-SMA) (Figure 5A), transforming growth
factor-b1( T G F - b1) (Figure 5B), Col-1 (Figure 6A) and
Col-3 (Figure 6B) had a marked elevation. The expression
of a-SMA (Figure 5A), TGF-b1( F i g u r e5 B ) ,C o l - 1
(Figure 6A) and Col-3 (Figure 6B) was significantly
down-regulated in the livers of mice treated with FZHY
or FZHY plus hemin compared with that administrated
with MCD diet alone.
Discussion
A suitable animal model that can reflect the characteristic
metabolic changes and the typical histological lesions of
progressive fibrosing steatohepatitis is critical for the eva-
luation of the therapeutic property of a compound [10].
We used a MCD dietary mouse model for this study,
which has been demonstrated typical nutritional fibrotic
changes resemble the human beings [10]. Following MCD
Table 1 Primers for real-time quantitative PCR analysis
Gene Product length Primer sequences
HO-1 427 bp F 5’-AACAAGCAGAACCCAGTCTATG-3’
R5 ’-TGAGCAGGAAGGCGGTCTTA-3’
CYP2E1 199 bp F 5’-AACAGAGACCACCAGCACA-3’
R5 ’-GGAAGGGACGAGGTTGATGA-3’
TNF-a 79 bp F 5’-GAACTGGCAGAAGAGGCACT-3’
R5 ’-AGAAGAGGCTGAGACATAGGC-3’
IL-6 85 bp F 5’-TACCACTCCCAACAGACCTG-3’
R5 ’-TCTCATTTCCACGATTTCCCAG-3’
a-SMA 162 bp F 5’-ATGATGCTCCCAGGGCTGTT -3’
R5 ’-TGGTGATGATGCCGTGTTCT-3’
TGF-b18 5 b p F 5 ’-CCGCAACAACGCCATCTATG -3’
R5 ’-TGCTTCCCGAATGTCTGACG-3’
Col-1 108 bp F 5’-TGACTGGAAGAGCGGAGAGT-3’
R5 ’-GTAGGGAACACACAGGTCTGA-3’
Col-3 61 bp F 5’-CTGGTGCTAAGGGTGAAGTTG-3’
R5 ’-TGTCCTGGTGAGCCATTTGAG-3’
GAPDH 120 bp F 5’-TGAACGGGAAGCTCACTGG-3’
R5 ’-GCTTCACCACCTTCTTGATGTC-3’
Abbreviations: HO-1 heme oxygenase-1, CYP2E1 cytochrome p4502E1, TNF-a
tumor necrosis factor-alpha, IL-6 interleukin-6, a-SMA a-smooth muscle actin,
TGF-b1 transforming growth factor beta 1, Col-1 collagen type I, Col-3 collagen
type III, GAPDH glyceraldehyde 3-phosphate dehydrogenase
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severe pattern of steatohepatitis with typical histopathol-
ogy, hepatocyte steatosis and necrosis, inflammatory cell
infiltration, fibrosis in the pericellular, perisinusoidal and
portal area. In accordance with these findings, a significant
elevation of serum AST and ALT was presented in MCD
diet feeding mice than that in the control. Liver injury
could be attenuated by FZHY administration with or with-
out hemin, as evidenced by diminished histological
steatosis, inflammation and fibrosis, as well as significantly
lowered serum ALT and AST levels. The combination of
FZHY and hemin showed a synergetic effect. These results
clearly indicated that FZHY modulated hepatic lipid
homeostasis and alleviated liver inflammation and fibrosis.
In accordance with our finding, Liu et al. showed that
FZHY inhibited inflammatory activity, improved the con-
tents of serum albumin and gamma-glutamyltransferase
activities [4].
Figure 1 Effect of the MCD diet and treatment with FZHY and hemin on: (A) Serum alanine aminotransferase (ALT); (B) Serum
aspartate aminotransferase (AST); (C) Hepatic malondialdehyde (MDA) content. Data are expressed as the mean ± SD (n = 6 per group).
*P < 0.001, compared with control group;
#P < 0.05,
##P < 0.01, compared with MCD group;
$P < 0.01,
$$P < 0.001, compared with MCD + FZHY
group;
ΔP < 0.05,
ΔΔP < 0.01, compared with MCD + Hemin group.
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Page 4 of 10Figure 2 Histopathological changes of liver sections in mice under various treatment conditions. Hematoxylin and eosin stained (A) and
Masson trichromatismstained (B) liver sections from mice liver (Original magnification, ×200)
Figure 3 Effect of FZHY and hemin on hepatic CYP2E1 and HO-1 expression. mRNA expression of CYP2E1 (A1) and HO-1 (B1) were
determined by quantitative real-time PCR; protein levels of CYP2E1 (A2) and HO-1 (B2) were detected by Western blot. Data are expressed as the
mean ± SD (n = 6 per group). *P < 0.05, *** P < 0.001, compared with control group;
#P < 0.05,
##P < 0.01,
###P < 0.001, compared with MCD group;
$$P < 0.01,
$$$P < 0.001, compared with MCD + FZHY group;
ΔP < 0.05,
ΔΔP < 0.01,
ΔΔΔP < 0.001, compared with MCD + Hemin group.
Jia et al. Lipids in Health and Disease 2012, 11:45
http://www.lipidworld.com/content/11/1/45
Page 5 of 10According to the “two hit” hypothesis proposed by Day
and James [11], appearance of oxidative stress, overex-
pression of pro-inflammatory cytokines and mitochon-
drial dysfunction are the key pathogenic factors involved
in development of necroinflammation and ultimately
fibrosis and cirrhosis, which are potentially major
therapeutic targets in NASH. Oxidative stress, triggered
by the accumulation of fatty acids and excessive lipid per-
oxidation products, leads to mitochondrial dysfunction,
hepatic cytochrome CYP2E1 expression, hepatocellular
apoptosis and inflammatory cells recruitment, then con-
tributes to stellate cells activation, collagen synthesis and
Figure 4 Effect of FZHY and hemin on expression of hepatic inflammatory factors in MCD diet-induced fibrosing steatohepatitis.
mRNA expression of TNF-a (A), IL-6 (B) were determined by quantitative real-time PCR. Data are expressed as the mean ± SD (n = 6 per group).
*P < 0.001, compared with control group;
#P < 0.05,
##P < 0.01,
###P < 0.001, compared with MCD group;
$$P < 0.01,
$$$P < 0.001, compared with
MCD + FZHY group;
ΔΔP < 0.01, compared with MCD + Hemin group.
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process, HO-1 plays a crucial role in maintaining cellular
homeostasis [14]. Under physiologic conditions HO-1
typically occurs at low to undetectable levels in liver but
undergoes a rapid transcriptional activation and
expresses in both Kupffer cells and hepatocytes as
response to noxious stimuli [15]. HO-1 induction is con-
sidered to be an adaptive cellular response to survive
exposure to environmental stresses. Our previous studies
demonstrated that up-regulation HO-1 expression played
a vital role in suppressing of oxidative stress, inflamma-
tion and fibrosis in various pathological conditions
[16-19]. In the present study, we found enhanced oxida-
tive stress in the MCD diet fed mice as demonstrated by
significantly increased MDA content, the mRNA and
protein expression of CYP2E1. Administration of FZHY
significantly reduced hepatic MDA content; suppressed
expression of CYP2E1 and induced expression of HO-1
in both mRNA and protein levels, which were concomi-
tant with improved liver histology. These results indi-
cated that FZHY had a protective effect on liver injury
through inhibiting oxidative stress by mediating key oxi-
dative stress related factors CYP2E1 and HO-1. In line
with our results, decreasing serum ALT, AST and MDA
content, improving SOD activity by FZHY had also been
observed by others in a chemical induced liver damage
animal model [20] and the herbs in FZHY showed a
coordinated effect [21].
During the inflammatory process, fibrogensis is part of
the wound-healing reaction. The activated Kupffer cells
secret pro-inflammatory cytokines such as TNF-a and
IL-6, triggers the production of other pro-inflammatory
cytokines and fibrogenic factors (e.g. TGF-b1), which
futher amplify the profibrogenic actions of HSCs [22,23].
TNF-a and IL-6 are important genes in modulating che-
mokine and cell adhesion molecule expression, promot-
ing the accumulation of mononuclear leukocytes,
stimulating stellate cells activation and collagen synthesis
[24,25]. A positive correlation has been found between
hepatic TNF-a, IL-6 expression and stage of fibrosis in
patients with NASH [26,27]. In this study, we also found
the significantly higher levels of hepatic TNF-a and IL-6
in mice fed with MCD diet. However, administration of
FZHY significantly reduced the hepatic expression of
TNF-a and IL-6 compared with mice fed with MCD diet
alone. Moreover, the combination of FZHY and hemin
further decreased these cytokines expression. These
results suggest that FZHY possesses anti-inflammatory
Figure 5 Effect of FZHY and hemin on hepatic a-SMA and TGF-b1 expression in MCD diet-induced fibrosing steatohepatitis.m R N A
expression of a-SMA (A1) and TGF-b1 (B1) were determined by quantitative real-time PCR; protein levels of a-SMA (A2) and TGF-b1 (B2) were
detected by Western blot. Data are expressed as the mean ± SD (n = 6 per group). *P < 0.001, compared with control group;
#P < 0.05,
##P <
0.01, compared with MCD group;
$P < 0.05,
$$P < 0.01, compared with MCD + FZHY group;
ΔP < 0.05,
ΔΔP < 0.01, compared with MCD + Hemin
group.
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matory and pro-fibrotic mediators TNF-a and IL-6,
which is beneficial for the treatment of fibrosing
steatohepatitis.
In response to oxidative stress, inflammatory cytokines
and endothelial matrix alternation caused by chronic liver
damage, HSCs undergo a process of transdifferentiation to
acquire a myofibroblastic phenotype accompanied by a
high expression of a-SMA [28]. HSCs play an unequivocal
role in excessive production and accumulation of extracel-
lular matrix in liver fibrosis [29]. It was known that phy-
siologic ECM consists mainly of non-fibrillar collagen,
proteoglycans and glycoproteins. Under pathologic condi-
tions the composition of ECM changes into a more fibril-
lar character with elevated proportion of type I and III
collagen, laminin, and fibronectin [30]. We found that the
mRNA and protein expression of a-SMA, Col-1 and Col-
3 clearly increased in the livers of MCD diet mice, indicat-
ing an increase of stellate cell activation and excessive
ECM deposition. Administration of FZHY with or without
hemin could reduce the expression of a-SMA, Col-1 and
Col-3, suggesting that the HSCs activation and collagen
synthesis were inhibited by FZHY. Consistent with our
findings, previous studies demonstrated that FZHY could
inhibit HSC activation [31,32], decrease a-SMA protein
expression and Col-1 secretion in liver fibrosis induced by
chemical toxin in rats [2,33].
Among the wide variety of cytokines and growth factors
secreted by HSC, TGF-b1 plays a predominant role in
impacting on collagen metabolism and proliferation. TGF-
b1 knockout mice have shown reduced collagen accumu-
lation in response to liver injury compared to that of nor-
mal mice [34]. Animal experiments have demonstrated
notable anti-fibrotic effect for liver fibrosis using different
strategies to block TGF-b1 [35-38]. Moreover, TGF-b1
gene silencing could significantly decreased concentration
of pro-inflammatory cytokine TNF-a, suggesting TGF-b1
gene silencing will decrease liver inflammation [39]. In our
study, the mRNA and protein expression of TGF-b1i s
higher in the livers of mice feeding MCD diet compared
with that in the control mice. Treatment with FZHY with
or without hemin significantly blunted the expression of
TGF-b1. Therefore, anti-fibrotic effect of FZHY was
mediated by inhibiting the expression of TGF-b1. This
effect was supported by observations from others that
FZHY significantly reduced collagen deposition [40],
down-regulate the protein expression of a-SMA [2,33,41]
and TGF-b1 [31].
Figure 6 Effect of FZHY and hemin on hepatic Col-1 and Col-3 expression in MCD diet-induced fibrosing steatohepatitis.m R N A
expression of Col-1 (A1) and Col-3 (B1) were determined by quantitative real-time PCR; protein levels of Col-1 (A2) and Col-3 (B2) were detected
by Western blot. Data are expressed as the mean ± SD (n = 6 per group). *P < 0.001, compared with control group;
#P < 0.05,
##P < 0.01,
###P <
0.001, compared with MCD group;
$P < 0.05,
$$$P < 0.001, compared with MCD + FZHY group;
ΔP < 0.05,
ΔΔP < 0.01,
ΔΔΔP < 0.001, compared
with MCD + Hemin group.
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FZHY in protection against nutritional liver fibrosis
through suppressing oxidative stress, inflammatory factors
and HSCs activation in experimental nutritional steatohe-
patitis, which were associated with up-regulation of anti-
oxidant gene HO-1, down-regulation of pro-oxidant gene
CYP2E1, inflammatory cytokines TNF-a, IL-6, pro-fibro-
genic factors a-SMA, TGF-b1, Col-1 and Col-3.
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